IBIO Profile
iBio, Inc., a prominent biotechnology firm established in 2008 and headquartered in Bryan, Texas, specializes in providing contract development and manufacturing services to a diverse array of collaborators and third-party customers across the United States. Operating through two distinct segments, Biopharmaceuticals and Bioprocessing, the company is at the forefront of advancing therapeutic solutions and vaccine development.
The company's pipeline features notable candidates such as IBIO-100, its lead anti-fibrotic therapy targeting systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is actively developing vaccine candidates including IBIO-202, designed to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and IBIO-400 for classical swine fever treatment. iBio also engages in the production of recombinant proteins for third-party clients, alongside offering comprehensive process development, manufacturing, and bioanalytical services.
Strategic collaborations underscore iBio's commitment to innovation and expansion. The company has secured significant partnerships, including licensing agreements with the University of Pittsburgh, The Texas A&M University System for plant-made biopharmaceuticals, and the University of Natural Resources and Life Sciences, Vienna. Additionally, iBio has a collaboration agreement with RubrYc, enhancing its capabilities in biopharmaceutical research and development.
Looking ahead, iBio continues to leverage its cutting-edge technologies and strategic alliances to drive growth and address emerging healthcare challenges. With a robust portfolio and a strong foundation in bioprocessing expertise, the company remains poised to deliver impactful solutions that advance medical care and improve patient outcomes globally.
|
